FUNDING FLAGSHIP 2 ( 2014 - 2020 )
Sydney Vital : $ 874 , 464
External Sources : $ 2 , 251 , 933
Item 1 28%
33.2%
66.8%
Item 2 72%
External Sources include : Novartis , Sirtex Medical , PETNET Solutions , ANSTO , IPSEN , Varian
RESEARCH SUCCESSES
Success in securing external funding from NHMRC through the highly competitive Investigator Grant awarded to Dr David Chan . Leading a randomised clinical trial on PRRT vs PRRT + chemotherapy vs chemotherapy in patients with metastic neuroendocrine tumours . Achieved accreditation as an ENETS ( European Neuro - Endocrine Tumour Society ) Centre of Excellence . Provision of a comprehensive image bank of NETPET ( Positron Emission Tomography ) scans in NSW for collaborative research . Attracted external funding equal to more than 2 . 5 times the sum of the base funding for the Flagship .
PATIENT OUTCOMES
Better outcomes for NET patients achieved in collaboration with the Sydney Vital NET TCE . CINSW impact report generated on Lu - DOTATATE outcomes for patients with advanced neuroendocrine tumours . Collaboration with Coviu on the development of a “ virtual MDT ” application which allows remote access to medical specialists at the weekly MDT meeting . Conducted three Q & A forums that have engaged patients , carers & GPs . Ran an information update session on NETs for General Practitioners ( Primary Health Network ).
P A G E
1 5
Made with FlippingBook - professional solution for displaying marketing and sales documents online